ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early and in ...
Approximately 3% of adults in the United States have psoriasis, with a higher prevalence among older adults, individuals with overweight or obesity, and non-Hispanic White individuals, according to ...
Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...
People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, a new study says. Psoriasis patients taking GLP-1 drugs had a 78% lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback